ResMed Management

Management criteria checks 4/4

ResMed's CEO is Mick Farrell, appointed in Mar 2013, has a tenure of 11.08 years. total yearly compensation is $13.87M, comprised of 8.1% salary and 91.9% bonuses, including company stock and options. directly owns 0.3% of the company’s shares, worth $82.23M. The average tenure of the management team and the board of directors is 3.1 years and 8.4 years respectively.

Key information

Mick Farrell

Chief executive officer

US$13.9m

Total compensation

CEO salary percentage8.1%
CEO tenure11.1yrs
CEO ownership0.3%
Management average tenure3.1yrs
Board average tenure8.4yrs

Recent management updates

Shareholders May Find It Hard To Justify Increasing ResMed Inc.'s (NYSE:RMD) CEO Compensation For Now

Nov 10
Shareholders May Find It Hard To Justify Increasing ResMed Inc.'s (NYSE:RMD) CEO Compensation For Now

Recent updates

ResMed Inc.'s (NYSE:RMD) Popularity With Investors Is Clear

Apr 18
ResMed Inc.'s (NYSE:RMD) Popularity With Investors Is Clear

With EPS Growth And More, ResMed (NYSE:RMD) Makes An Interesting Case

Mar 22
With EPS Growth And More, ResMed (NYSE:RMD) Makes An Interesting Case

Capital Investments At ResMed (NYSE:RMD) Point To A Promising Future

Mar 10
Capital Investments At ResMed (NYSE:RMD) Point To A Promising Future

An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 30% Undervalued

Feb 12
An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 30% Undervalued

Why ResMed Is One Of My Top Picks In 2024

Jan 22

A First Look At ResMed

Jan 09

ResMed Inc.'s (NYSE:RMD) Share Price Could Signal Some Risk

Dec 20
ResMed Inc.'s (NYSE:RMD) Share Price Could Signal Some Risk

Why You Should Care About ResMed's (NYSE:RMD) Strong Returns On Capital

Dec 06
Why You Should Care About ResMed's (NYSE:RMD) Strong Returns On Capital

Shareholders May Find It Hard To Justify Increasing ResMed Inc.'s (NYSE:RMD) CEO Compensation For Now

Nov 10
Shareholders May Find It Hard To Justify Increasing ResMed Inc.'s (NYSE:RMD) CEO Compensation For Now

Are Investors Undervaluing ResMed Inc. (NYSE:RMD) By 41%?

Nov 01
Are Investors Undervaluing ResMed Inc. (NYSE:RMD) By 41%?

ResMed: Weight-Loss Drug Worries Provide Buying Opportunity

Oct 28

ResMed: Stock Re-Rating To 20x Forward P/E Is A Buy Opportunity

Sep 12

ResMed Has Become A Steal (Rating Upgrade)

Aug 10

ResMed's (NYSE:RMD) Shareholders Will Receive A Bigger Dividend Than Last Year

Aug 07
ResMed's (NYSE:RMD) Shareholders Will Receive A Bigger Dividend Than Last Year

ResMed (NYSE:RMD) Has Some Way To Go To Become A Multi-Bagger

Jul 30
ResMed (NYSE:RMD) Has Some Way To Go To Become A Multi-Bagger

Here's Why We Think ResMed (NYSE:RMD) Might Deserve Your Attention Today

Jul 16
Here's Why We Think ResMed (NYSE:RMD) Might Deserve Your Attention Today

Compound Your Wealth With ResMed

Jul 04

A Look At The Fair Value Of ResMed Inc. (NYSE:RMD)

Jul 02
A Look At The Fair Value Of ResMed Inc. (NYSE:RMD)

We Think ResMed (NYSE:RMD) Can Stay On Top Of Its Debt

May 26
We Think ResMed (NYSE:RMD) Can Stay On Top Of Its Debt

ResMed (NYSE:RMD) Could Be Struggling To Allocate Capital

Apr 24
ResMed (NYSE:RMD) Could Be Struggling To Allocate Capital

Here's Why ResMed (NYSE:RMD) Has Caught The Eye Of Investors

Apr 09
Here's Why ResMed (NYSE:RMD) Has Caught The Eye Of Investors

A Look At The Intrinsic Value Of ResMed Inc. (NYSE:RMD)

Mar 26
A Look At The Intrinsic Value Of ResMed Inc. (NYSE:RMD)

ResMed goes ex dividend tomorrow

Feb 07

ResMed (NYSE:RMD) Seems To Use Debt Quite Sensibly

Feb 06
ResMed (NYSE:RMD) Seems To Use Debt Quite Sensibly

ResMed: The GARP Story Continues, Technicals Showing Vital Signs

Jan 26

Why The 23% Return On Capital At ResMed (NYSE:RMD) Should Have Your Attention

Jan 23
Why The 23% Return On Capital At ResMed (NYSE:RMD) Should Have Your Attention

We Ran A Stock Scan For Earnings Growth And ResMed (NYSE:RMD) Passed With Ease

Dec 28
We Ran A Stock Scan For Earnings Growth And ResMed (NYSE:RMD) Passed With Ease

Calculating The Fair Value Of ResMed Inc. (NYSE:RMD)

Dec 16
Calculating The Fair Value Of ResMed Inc. (NYSE:RMD)

ResMed: Strong Earnings Growth Supports The High Valuation, Unclear Technical Trends

Nov 14

ResMed declares $0.44 dividend

Oct 27

These 4 Measures Indicate That ResMed (NYSE:RMD) Is Using Debt Reasonably Well

Oct 22
These 4 Measures Indicate That ResMed (NYSE:RMD) Is Using Debt Reasonably Well

ResMed raised to Buy at BofA citing Q1 beat

Oct 20

Why The 23% Return On Capital At ResMed (NYSE:RMD) Should Have Your Attention

Oct 10
Why The 23% Return On Capital At ResMed (NYSE:RMD) Should Have Your Attention

CEO Compensation Analysis

How has Mick Farrell's remuneration changed compared to ResMed's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023n/an/a

US$890m

Sep 30 2023n/an/a

US$907m

Jun 30 2023US$14mUS$1m

US$898m

Mar 31 2023n/an/a

US$863m

Dec 31 2022n/an/a

US$809m

Sep 30 2022n/an/a

US$786m

Jun 30 2022US$12mUS$1m

US$779m

Mar 31 2022n/an/a

US$779m

Dec 31 2021n/an/a

US$522m

Sep 30 2021n/an/a

US$500m

Jun 30 2021US$10mUS$1m

US$475m

Mar 31 2021n/an/a

US$457m

Dec 31 2020n/an/a

US$699m

Sep 30 2020n/an/a

US$680m

Jun 30 2020US$10mUS$1m

US$622m

Mar 31 2020n/an/a

US$513m

Dec 31 2019n/an/a

US$455m

Sep 30 2019n/an/a

US$419m

Jun 30 2019US$10mUS$967k

US$405m

Mar 31 2019n/an/a

US$446m

Dec 31 2018n/an/a

US$450m

Sep 30 2018n/an/a

US$335m

Jun 30 2018US$9mUS$934k

US$316m

Mar 31 2018n/an/a

US$307m

Dec 31 2017n/an/a

US$285m

Sep 30 2017n/an/a

US$352m

Jun 30 2017US$8mUS$890k

US$342m

Compensation vs Market: Mick's total compensation ($USD13.87M) is about average for companies of similar size in the US market ($USD13.05M).

Compensation vs Earnings: Mick's compensation has been consistent with company performance over the past year.


CEO

Mick Farrell (51 yo)

11.1yrs

Tenure

US$13,868,641

Compensation

Mr. Michael J. Farrell, also known as Mick, BE, SM, MBA, served as Director of Fullbay, Inc. since May 2023 until 2023. He serves as Member of Advisory Board at Green Sun Medical, LLC. He serves as the Chi...


Leadership Team

NamePositionTenureCompensationOwnership
Michael Farrell
CEO & Chairman11.1yrsUS$13.87m0.30%
$ 82.2m
Peter Farrell
Founderno dataUS$680.27k0.11%
$ 28.8m
Brett Sandercock
Chief Financial Officer18.3yrsUS$3.11m0.063%
$ 17.2m
Robert Douglas
Special Advisorless than a yearUS$6.67m0.18%
$ 48.9m
Kaushik Ghoshal
Chief Commercial Officer - SaaS2.2yrsUS$3.31m0.0088%
$ 2.4m
Amy Wakeham
Chief Investor Relations Officerless than a yearno datano data
Michael Rider
Chief Legal Officerless than a yearno data0.0045%
$ 1.2m
Jim Ellis
Chief Compliance Officer6.3yrsno datano data
Yvonne-Katrin Pucknat
Chief Marketing Officerless than a yearno datano data
Vered Keisar
Chief People Officer3.1yrsno datano data
Hemanth Reddy
Chief Strategy Officer9.3yrsno datano data
Andrew Price
Chief Supply Chain Officer6.8yrsno datano data

3.1yrs

Average Tenure

59.5yo

Average Age

Experienced Management: RMD's management team is considered experienced (3.1 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Michael Farrell
CEO & Chairman11.1yrsUS$13.87m0.30%
$ 82.2m
Peter Farrell
Founder34.8yrsUS$680.27k0.11%
$ 28.8m
Richard Sulpizio
Independent Director18.7yrsUS$340.06k0.010%
$ 2.8m
Ronald Taylor
Lead Independent Director19.3yrsUS$372.56k0.014%
$ 3.9m
Jan De Witte
Independent Non-Executive Director4.9yrsUS$320.06k0.0042%
$ 1.1m
Harjit Gill
Independent Director5.4yrsUS$320.06k0.0049%
$ 1.3m
Carol Burt
Independent Director10.4yrsUS$360.06k0.010%
$ 2.8m
Karen Drexler
Independent Director6.4yrsUS$320.06k0.0054%
$ 1.5m
Desney Tan
Independent Director2.4yrsUS$320.06k0.0014%
$ 382.9k
John Hernandez
Independent Director2.4yrsUS$320.06k0.0014%
$ 382.9k

8.4yrs

Average Tenure

61yo

Average Age

Experienced Board: RMD's board of directors are considered experienced (8.4 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.